Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SUNHO
BIOPHARMACEUTICAL (CHINA) CO. LTD

Sunho Biologics, Inc.
盛禾生物控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2898)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO APPOINTMENT OF INDEPENDENT INTERNAL CONTROL CONSULTANT AND CONTINUED SUSPENSION OF TRADING

Reference is made to the announcement of Sunho Biologics, Inc. ("**Company**") dated August 4, 2026 in relation to the appointment of Independent IC Consultant ("**Announcement**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to provide the following supplementary information in relation to the appointment of Independent IC Consultant.

AUDIT COMMITTEE'S ASSESSMENT ON THE INDEPENDENT IC CONSULTANT

In addition to the information disclosed in the Announcement, the Company would like to supplement the following information in relation to the factors considered by the Audit Committee in respect of the appointment of the Independent IC Consultant:

1. *Independence:* the Independent IC Consultant is an independent third party not connected with any of the substantial Shareholders or Directors. The Independent IC Consultant has confirmed that (i) it does not act for the Company, its connected persons (as defined under the Listing Rules), or any persons or entities involved in, or aware of, the irregularities; (ii) it has not been involved in any transactions or arrangements relating to the irregularities; (iii) it is independent from and not connected with the Company, its subsidiaries, Directors, chief executive, substantial Shareholder(s) or any other connected person (as defined under the Listing Rules) and parties involved in or aware of the matters under its engagement; and (iv) it does not have any shareholding, directly or indirectly, in the Company or any of its subsidiaries, or any right or option (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member company of the Group.

2. *Credentials, qualifications and resources:* the Independent IC Consultant will assign eight personnel for carrying out the internal control review work. The team comprises one engagement partner, one consultant, two managers, and four internal control specialists. Credentials and qualifications of the core team members designated by the Independent IC Consultant are as follows:

   (i) the engaging partner for the internal control review work has 20 years of solid experience in managing a wide range of fields, such as auditing, financial reporting, internal control and capital market transactions. His clientele includes a number of sizable entities from the healthcare, technology, pharmaceutical, tourism, manufacturing and property development industries. He is a member of the Hong Kong Institute of Certified Public Accountants, a member of the Association of Chartered Certified Accountants, and a member of The Hong Kong Institute of Directors;

   (ii) the internal control consultant supporting the engaging partner has over 30 years of experience in the professional fields, such as auditing, information technology auditing, training, financial management, company secretarial services and administration, information systems management, internal auditing, information security systems, compliance, and corporate risk management. He holds professional qualifications from FCPA, ACA, CISA, FHKIoD, and IIA, and he is the convener of the Financial Services Interest Group Organizing Committee;

   (iii) the senior manager and manager responsible for the daily execution of the internal control review work possess over 20 and 10 years of experience, respectively, in auditing and internal control review, and they are members of the Association of Chartered Certified Accountants (ACCA) and the Chinese Institute of Certified Public Accountants (CICPA).

   In addition to the above team members, four internal control specialists will be assigned and they will be responsible for compiling data request lists and questionnaires, conducting interviews, and collecting data.

3. *Experience:* the Independent IC Consultant is experienced in providing internal control review for companies listed on the Stock Exchange. In particular, they have provided internal control review for long-suspended issuers and with internal control review being a resumption condition.

Based on the above, the Audit Committee concluded that the Independent IC Consultant is independent and possesses the credentials, qualifications, experience and resources to conduct the Independent IC Review.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, September 14, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.